Conference on 9th Annual Pricing and Reimbursement(

Conference on 9th Annual Pricing and Reimbursement
Delivering practical solutions and initiating winning strategies to streamline
your P&R decisions

27th - 29th September 2010, BSG Conference Centre, London, UK

Key Speakers

Dr. Jorge Mestre-Ferrandiz, Senior Economist, Office of Health Economics,
Andrea Rappagliosi, Vice President European Government Affairs & Head of
Brussels Office, Glaxosmithkline,
Anne-Toni Rodgers, Senior Director, Government Affairs and Public Policy –
Europe Middle East and Africa, Baxter World Trade,
Janice Haigh, Senior Director, Pricing and Market Access – Europe, Astellas
Sarah Pitluck, Director, Global Government Affairs, Alexion Pharmaceuticals,
Luis Gonzalez Vaque, Member, British Institute of International and
Comparative Law (BIICL),
Trevor Leighton, VP Pricing & Reimbursement, Shire,
Dr. Razmic Gregorian, Director, Simon-Kucher & Partner,
Prof. Mondher Toumi, Professor Market Access, University of Lyon,
Donald Macarthur, independent consultant & Principal, Justpharmareports,
Dr. Brian Smith, Editor, Journal of Medical Marketing, Pragmedic,
Dermot Glynn, Chairman, Europe Economics,
Adam Barak, Head of International Pricing and Reimbursement, United BioSource
Nicole Mather, Consulting, Deloitte.
Conference Introduction
Reasons to register today:
• Discover the best methodologies to sustain effect of global recession
• Examine how to price to gain incremental patients in the emerging markets
• Assess the latest developments in HTA policy
• Analyse the impact of the healthcare reform bill in the US
• Learn how to develop an effective risk management plan
• Gain an insight of your product’s potential price profile and optimise future
• Be part of the unparalleled networking
Who should attend?

VPs, Directors, Heads and Managers of:
• Pricing and Reimbursement
• Reimbursement & Market Access
• Strategic Pricing
• Price Monitoring
• Health Economics
• Finance
• Commercial Pricing
• Economics and Government Affairs
• International Trade and Market Policy
• Parallel Trade
• Research and Development
• Business Strategy
• Sales & Marketing
• Brand Management
• Corporate Strategy
• Operations
• Regulatory Affairs
• Public Affairs
• Outcomes Research
• Contracts
• Legal
Others: Health Policy Advisors, Academics, Solution providers &
consultants, Patient Representatives.
Pre-Conference Interactive Workshop
Monday 27th September, 2010,
Bottom of the Pyramid: How to price to gain
incremental patients in the emerging markets
About the workshop:
• In which emerging markets does pricing by ability to pay matter the most?
• How should MNCs customise their portfolios in the emerging markets to maximise
access by customer segment?
• What is the role of reference pricing in emerging markets and is there a
creeping discipline for this outside Europe?
• How should branded generics be priced relative to other generic manufacturer
competitors in the emerging markets?
• What type of relationship exists between price and volume in the emerging
• Markets of consideration include, but are not limited to China, India, Brazil,
Russia, Mexico, Turkey, and Poland
Presentation: HTA’s New Frontier: Asia’s Emerging
Evidence Networks
• What is the progress of HTA adoption in key emerging markets (Korea, Taiwan,
Thailand, China, India)?
• How can we predict the timing of HTA adoption, implementation, and reliance
using macroeconomic indicators?
• Where will these new agencies source their analyses manufacturers, domestic
academic institutions, or international HTA agencies?
• Which therapeutic areas are at greatest risk, and in which markets?
About your workshop leader:
Cyrus Chowdhury is Vice President and leader of the global market access
practice with Insight Strategy Advisors, possessing years of biopharmaceutical
management consulting experience in the emerging and developed markets. His
areas of expertise are global pricing, market access and portfolio optimisation.
He has deep therapeutic area knowledge in CNS, oncology and inflammation, though
his experience canvases many other high growth areas within the clinical realm.
Mr. Chowdhury has managed and executed pricing and market access projects around
the world, including within both developed and emerging economies. He possesses
experience and a working knowledge of pharmaceutical pricing and  market access
policies in the US, Japan, UK, Germany, France, Spain, Italy, Canada markets.
Additionally, he spent time in Asia managing pricing and market access projects
in China, India, Korea and Australia. Today, his network spans throughout
Central and Eastern Europe, Asia-Pacific, the Middle East, Latin America and
Africa. Prior to joining ISA, Mr. Chowdhury was a Consultant with Cambridge
Pharma Consultancy (now IMS), where he acquired extensive training and
experience through years of project work. Additionally, Mr. Chowdhury served as
a special independent consultant to Genzyme. In this capacity, he developed a
comprehensive global parallel trade defense strategy and market entry sequencing
for Genzyme while in Oxford. Mr. Chowdhury also spent two years with Fidelity
Investments, specifically focusing on emerging biopharmaceutical and specialty
pharmaceutical companies in CNS and Women’s Health. In addition to his
commercial experiences, Mr. Chowdhury also performed clinical research with the
UCLA School of Medicine in the Department of Urology. He published on such
topics as pelvic floor disorders and bio-identical hormone replacement therapy.
Mr. Chowdhury earned a Master in International Health Policy & Economics, with
High Distinction from the London School of Economics, and a Bachelor of Arts in
Neuroscience from Boston University, summa cum laude. He is frequently invited
to speak in the EU, Asia and US on topics including emerging markets and global
market access strategy.
Day 1
Tuesday 28th September 2010
09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 HTA/Regulators interaction: An industry perspective of the pan-European
• Assessing value in healthcare
• Reviewing the opportunities for improvement of HTA/Regulators interaction
• Examining the limitations of an integrated approach

Andrea Rappagliosi,
Vice President European Government Affairs & Head of Brussels Office,

10:50 Access mechanisms for orphan drugs: A comparative study of selected
european countries
• Introduction: Orphan drug regulation and landscape
• Objectives and methods of the study
• Overarching themes
• Coverage decisions
• Summary and conclusions

Dr Jorge Mestre-Ferrandiz
Senior Economist, Office of Health Economics

11:30 Morning refreshments

11:50 Assessment of EU market growth of private healthcare vs public.
Increasing private provision of healthcare will involve addressing traditional
ideological concerns, making private healthcare more attractive
and driving accountability of public healthcare providers
• Where is the trend line heading? Are traditional levels of public healthcare
provision sustainable?
• What is the landscape for private healthcare provision in Europe?

To know more and to buy a copy of
your report feel free to visit :


Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: